Safety matters a lot too, and the combo trial likely started out first year enrollment slowly to observe, study and evaluate trial parameters going forward. My guess here is that it is very tricky to time completion of a phase three trial with enrollment timing of the combo trial. I could expound, but I guess most people already know what those might be. I do see the recent UCLA PR on the combo trial as an indication it is ok to move toward enrollment completion for the combo trial now. I suspect they are witnessing something historic.
Market Data 
Markets 
AI
